BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models-Reference-Cited by-同舟云学术

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

Published:2016-08-22 Issue:9 Volume:126 Page:3479-3494
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Kagoya Yuki,Nakatsugawa Munehide,Yamashita Yuki,Ochi Toshiki,Guo Tingxi,Anczurowski Mark,Saso Kayoko,Butler Marcus O.,Arrowsmith Cheryl H.,Hirano Naoto

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference58 articles.

1. From cancer immunosurveillance to cancer immunotherapy

2. Cancer immunotherapy: moving beyond current vaccines

3. Targeting tumours with genetically enhanced T lymphocytes

4. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

5. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy;Frontiers in Immunology;2024-08-30

2. Stem-like CD8+ T cells in cancer;Frontiers in Immunology;2024-08-15

3. Immune infiltration analysis based on pyroptosis-related gene in metabolic dysfunction-associated fatty liver disease;Heliyon;2024-08

4. Epigenetic Modulation of Immune Cells: Mechanisms and Implications.;Advances in Biological Regulation;2024-08

5. Altered cancer metabolism and implications for next-generation CAR T-cell therapies;Pharmacology & Therapeutics;2024-07